CSPC Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)

Announcements & Notices       

2024-December-20	VOLUNTARY ANNOUNCEMENT - SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-December-20	VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-December-20	VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-December-19	CONNECTED TRANSACTIONS AND CONTINUING CONNECTED TRANSACTION (in PDF)
2024-December-13	VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYH2039 WITH BEIGENE (in PDF)
2024-December-9	VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF SYHX2011 FOR THE TREATMENT OF ADVANCED BREAST CANCER (in PDF)
2024-December-6	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2024-December-6	APPOINTMENT AND RESIGNATION OF EXECUTIVE DIRECTOR (in PDF)
2024-December-4	VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-December-4	VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA (in PDF)
2024-November-26	VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION (in PDF)
2024-November-15	QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024 (in PDF)
2024-November-12	VOLUNTARY ANNOUNCEMENT - BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-November-5	DATE OF BOARD MEETING (in PDF)
2024-October-31	PROFIT WARNING (in PDF)
2024-October-25	VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION (in PDF)
2024-October-23	UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024 (in PDF)
2024-October-8	VOLUNTARY ANNOUNCEMENT - OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA (in PDF)
2024-October-8	VOLUNTARY ANNOUNCEMENT - CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA (in PDF)
2024-October-7	VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA (in PDF)
2024-September-30	VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA (in PDF)
2024-September-20	VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-September-19	VOLUNTARY ANNOUNCEMENT - FURTHER SHARE BUY-BACK PLAN OF UP TO HK$5 BILLION (in PDF)
2024-September-16	VOLUNTARY ANNOUNCEMENT - AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-September-9	VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-September-9	VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DR. LIU YONGJUN AS EXECUTIVE PRESIDENT AND PRESIDENT OF GLOBAL RESEARCH AND DEVELOPMENT (in PDF)
2024-August-28	VOLUNTARY ANNOUNCEMENT - DEXRAZOXANE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-August-21	2024 INTERIM DIVIDEND (in PDF)
2024-August-21	2024 INTERIM RESULTS (in PDF)
2024-August-16	UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2024 (in PDF)
2024-August-9	DATE OF BOARD MEETING (in PDF)
2024-August-9	VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION (in PDF)
2024-July-25	CONTINUING CONNECTED TRANSACTIONS - PURSUANT TO RULE 14A.60(1) OF THE LISTING RULES (in PDF)
2024-July-11	VOLUNTARY ANNOUNCEMENT - mRNA RSV VACCINE (SYS6016) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-July-8	VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
2024-July-5	VOLUNTARY ANNOUNCEMENT - ROXADUSTAT CAPSULES OBTAIN DRUG REGISTRATION APPROVAL (in PDF)
2024-June-28	VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA (in PDF)
2024-June-28	VOLUNTARY ANNOUNCEMENT - PALBOCICLIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-June-28	CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MASTER PURCHASE AGREEMENT (in PDF)
2024-June-25	VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-June-12	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-June-11	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-June-7	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-June-4	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-June-3	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-June-3	VOLUNTARY ANNOUNCEMENT - OLAPARIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-May-31	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-May-30	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-May-29	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2024-May-28	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2024-May-28	RETIREMENT OF EXECUTIVE DIRECTORS, APPOINTMENT OF EXECUTIVE DIRECTORS AND CHANGE OF AUTHORISED REPRESENTATIVE (in PDF)
2024-May-28	POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 MAY 2024 (in PDF)
2024-May-27	QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024 (in PDF)
2024-May-21	VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE RULES OF THE RESTRICTED SHARE AWARD SCHEME (in PDF)
2024-May-17	VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-May-14	DATE OF BOARD MEETING (in PDF)
2024-May-14	VOLUNTARY ANNOUNCEMENT - PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-April-26	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-April-26	VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
2024-April-25	NOTICE OF ANNUAL GENERAL MEETING (in PDF)
2024-April-24	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-April-23	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2024-April-22	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024 (in PDF)
2024-April-22	GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY (in PDF)
2024-April-19	CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MASTER SALES AGREEMENT (in PDF)
2024-April-15	EXERCISE OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME (in PDF)
2024-March-25	VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-March-22	VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2024-March-20	VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-March-20	CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER (in PDF)
2024-March-20	ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
2024-March-18	VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2024-March-14	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
2024-March-8	DATE OF BOARD MEETING (in PDF)
2024-February-5	VOLUNTARY ANNOUNCEMENT - INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL (in PDF)
2024-January-24	KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
2024-January-15	VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
2023	2023 Announcements & Notices
2022	2022 Announcements & Notices
2021	2021 Announcements & Notices
2020	2020 Announcements & Notices
2019	2019 Announcements & Notices
2018	2018 Announcements & Notices
2017	2017 Announcements & Notices
2016	2016 Announcements & Notices
2015	2015 Announcements & Notices
2014	2014 Announcements & Notices
2013	2013 Announcements & Notices
2012	2012 Announcements & Notices
2011	2011 Announcements & Notices
2010	2010 Announcements & Notices
2009	2009 Announcements & Notices
2008	2008 Announcements & Notices
2007	2007 Announcements & Notices
2006	2006 Announcements & Notices